Literature DB >> 176399

Immune reactivity in the Moloney strain of murine sarcoma virus oncogenesis: requirement of thymus-derived lymphocytes for in vivo protection.

D Collavo, A Colombatti, G Biasi, L Chieco-Bianchi, A J Davies.   

Abstract

To study the function of different lymphocyte populations in the Moloney strain of murine sarcoma virus (M-MuSV) tumorigenesis, we gave M-MuSV injections to CBA mice selectively deprived of thymus (T) lymphocytes by thymectomy, X-rradiation, and syngeneic bone marrow injection. Although no tumors appeared in the control group, 80% of the derived mice had tumors that grew progressively and ultimately killed them. In deprived mice, grafted with a syngeneic thymus (reconstituted mice) before or after an M-MuSV injection, tumors regressed or did not develop. Histologically, the lymph nodes and spleens of reconstituted mice, compared to those of deprived animals, showed repopulation of the thymus-dependent areas and prominent follicles in the cortex. Moreover, tumor tissue of reconstituted mice was extensively infiltrated by lymphocytes. To evaluate the number of lymphoid cells needed to prevent or regress M-MuSV tumors, we injected varying amounts of lymphoid cells into deprived mice. Even low lymphocyte numbers (10(6) cells) were sufficient to exert, in some cases, protection against M-MuSV tumorigenesis. This effect was not abolished by subsequent splenectomy or antilymphocyte serum treatment. Finally, deprived mice, given repeated injections of antiserum (hyperimmune) against M-MuSV, had tumors which appeared only after a prolonged latency. From these results, it is concluded that T-cell population integrity is important in affording total host protection against the M-MuSV tumors.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 176399     DOI: 10.1093/jnci/56.3.603

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  5 in total

1.  Dissecting the immune response to moloney murine sarcoma/leukemia virus-induced tumors by means of a DNA vaccination approach.

Authors:  G Milan; A Zambon; M Cavinato; P Zanovello; A Rosato; D Collavo
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

2.  Adoptive T cell immunotherapy of MSV-induced tumours in nude mice. Part I. Biology of tumour regression and recurrence.

Authors:  D F Tucker; R A Knight; P H Warne
Journal:  Clin Exp Metastasis       Date:  1983 Jul-Sep       Impact factor: 5.150

3.  Growth pattern of tumours in mice induced by murine Moloney sarcoma-virus and sarcoma-virus-transformed cells.

Authors:  F Weiland; E Weiland; M Mussgay
Journal:  Br J Cancer       Date:  1979-12       Impact factor: 7.640

4.  Nonproducer malignant tumor cells with rescuable sarcoma virus genome isolated from a recurrent Moloney sarcoma.

Authors:  E Weiland; M Mussgay; F Weiland
Journal:  J Exp Med       Date:  1978-08-01       Impact factor: 14.307

Review 5.  Characterization of gP85gag as an antigen recognized by Moloney leukemia virus-specific cytolytic T cell clones that function in vivo.

Authors:  F A van der Hoorn; T Lahaye; V Müller; M A Ogle; H D Engers
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.